Serious Neurological Adverse Events after Ivermectin – Do They Occur beyond the Indication of Onchocerciasis? (2018)

Peer-Reviewed Study · Chandler RE (Uppsala Monitoring Centre) · February 2018

Chandler RE (Uppsala Monitoring Centre), 2018-02: Review of 48 VigiBase reports of serious neurological events after ivermectin for non-onchocerciasis indications; 28 were retained and judged to support a causal role, though the author calls such events likely rare.

This series suggests that serious neurological adverse events observed with the use of ivermectin in the treatment of onchocerciasis may not be entirely explained by concomitant high burden loiasis infections.

Chandler RE (Uppsala Monitoring Centre), 2018-02: Review of 48 VigiBase reports of serious neurological events after ivermectin for non-onchocerciasis indications; 28 were retained and judged to support a causal role, though the author calls such events likely rare. C9, both sides at full strength. Study type: pharmacovigilance case series (VigiBase, WHO programme). Country: Sweden (Uppsala Monitoring Centre); cases from multiple countries. N: 48 reported, 20 excluded, 28 retained. Dose: not stated in the abstract captured. Funder/conflicts: not captured in the PubMed record; the author is employed at the Uppsala Monitoring Centre, which manages VigiBase. Supporting evidence cited: drug found in brain tissue in one case and symptom recurrence on re-exposure in three. The same abstract says 'the number of reported cases suggests that such events are likely rare'. Recommends investigating drug-drug interactions and mdr-1 polymorphisms – the same mechanism as IVA-43/IVA-44. Study type: uncontrolled series.